Slide 1: Fourth Quarter and Year-End 2024 Financial Results & Business Update
Fourth Quarter and Year-End 2024 Financial Results & Business Update February 12, 2025 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Highly Profitable, Self-Funding Business With Strong Balance Sheet
Highly Profitable, Self-Funding Business With Strong Balance Sheet EBITDA represents earnings before interest, tax, depreciation and amortization; earnings include share-based compensation expense. * Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial mea
Slide 4: Q4 & FY 2024 Financial and Operational Performance
Q4 & FY 2024 Financial and Operational Performance
Slide 5: FY 2024 Financial Results Summary
In millions FY 2024 Financial Results Summary Total Revenue In millions GAAP Net Income GAAP Earnings Per Share Diluted FY 2024 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024. FY 2023 results reflect reinstatement of certain U.S. royalties following the su
Slide 6: FY 2024 Profitability From Continuing Operations
In millions FY 2024 Profitability From Continuing Operations GAAP Net Income From Continuing Operations In millions Non-GAAP Net Income* From Continuing Operations EBITDA* From Continuing Operations In millions EBITDA represents earnings before interest, tax, depreciation and amortization; earnings
Slide 7: Q4 2024 Revenue Summary
Q4 2024 Revenue Summary In millions Q4’24 Q4’23 Total Proprietary Net Sales $307.7 $242.0 VIVITROL® $134.1 $102.4 ARISTADA®* $96.6 $83.4 LYBALVI® $77.0 $56.2 Manufacturing & Royalty Revenue $122.3 $135.5 Total Revenue $430.0 $377.5 *Inclusive of ARISTADA INITIO® **Reflects expiration of royalty on U
Slide 8: FY 2024 Revenue Summary
FY 2024 Revenue Summary In millions FY’24 FY’23 Total Proprietary Net Sales $1,083.5 $920.0 VIVITROL® $457.3 $400.4 ARISTADA®* $346.2 $327.7 LYBALVI® $280.0 $191.9 Manufacturing & Royalty Revenue $474.1 $743.4*** Total Revenue $1,557.6 $1,663.4*** *Inclusive of ARISTADA INITIO® **Reflects expiration
Slide 9: Alkermes: 2025 Financial Expectations
Alkermes: 2025 Financial Expectations* *These expectations are provided by the Company on Feb. 12, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconciliation of this non-GAAP financial measure to the most dire
Slide 10: 2024 Commercial Review
2024 Commercial Review
Slide 11: Topline Growth and Diversification Reflect Evolving Business
Topline Growth and Diversification Reflect Evolving Business *Inclusive of ARISTADA INITIO® **Licensed product (royalty & manufacturing revenue) Key Product Revenues ($M) $574 $715 $893 $1,049 $1,218
Slide 12: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations *These expectations are provided by the Company on Feb. 12, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. LYBALVI Quarterly Net Sales ($M) Q4’24 LYBALVI net sales of $77.0M r
Slide 13: LYBALVI Prescription Growth Trends
LYBALVI® Prescription Growth Trends Q4’24 total TRx: ~60,300 reflecting 5% sequential growth compared to Q3’24 *Source: IQVIA NPA Weekly Post-Launch TRx* (Through 1/31/2025) TRx Week
Slide 14: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) Q4’24 ARISTADA net sales were $96.6M FY’24 ARISTADA net sales were $346.2M Outlook: FY’25 net sales expected to range from $335M – $355M†* *Inclusive of ARISTADA INITIO® †These expectations are provided by the Company on Feb.
Slide 15: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) *These expectations are provided by the Company on Feb. 12, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q4’24 VIVITROL net sales were $13
Slide 16: Appendix
Appendix
Slide 17: Appendix: Amounts Included in Discontinued Operations
Appendix: Amounts Included in Discontinued Operations (In millions) Year Ended December 31, 2023 Three Months Ended March 31, 2024 Three Months Ended June 30, 2024 Three Months Ended September 30, 2024 Three Months Ended December 31, 2024 Year Ended December 31, 2024 Cost of goods manufactured and s
Slide 18: Appendix: Financial Results GAAP to EBITDA Adjustments
Appendix: Financial Results GAAP to EBITDA Adjustments (In millions) Year Ended December 31, 2024 Year Ended December 31, 2023 Net Income from Continuing Operations — GAAP $ 372.1 $ 519.2 Adjustments: Depreciation expense 27.4 36.9 Amortization expense 1.1 35.7 Interest income (42.5) (30.9) Interest
Slide 19: Appendix: Financial Results GAAP to Non-GAAP Adjustments
Appendix: Financial Results GAAP to Non-GAAP Adjustments (In millions) Year Ended December 31, 2024 Year Ended December 31, 2023 Net Income from Continuing Operations — GAAP $ 372.1 $ 519.2 Adjustments: Share-based compensation expense 96.6 92.7 Depreciation expense 27.4 36.9 Amortization expense 1.
Slide 20: Appendix: 2025 Guidance GAAP to EBITDA and Adjusted EBITDA
Appendix: 2025 Guidance GAAP to EBITDA and Adjusted EBITDA Projected GAAP and non-GAAP measures reflect the mid-points within the Company’s financial expectations ranges. (In millions) Year Ended December 31, 2023 Year Ending December 31, 2025 Projected Net Income — GAAP $ 190.0 Adjustments: Net int
Slide 21: (© 2025 Alkermes. All rights reserved.
www.alkermes.com (© 2025 Alkermes. All rights reserved.